InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.175 0.01 (6.06%)+
Announcement
Release
30 Jul 2026 9:55AM
Price at Release
$0.165
Full Release
download
Summary
Paradigm Biopharmaceuticals Ltd. highlighted significant progress in its Phase 3 osteoarthritis program during the June 2026 quarter. The company successfully completed enrollment in its global PARA_OA_012 study, anticipating the Interim Analysis and Phase 3 primary endpoint results in early 2027. An institutional Placement and a Share Purchase Plan significantly bolstered the company's funding, raising approximately A$21.38 million to support ongoing clinical trials, regulatory activities, and commercial readiness. Paradigm remains focused on maintaining high standards in clinical operations, advancing scientific research, and exploring regional and global licensing opportunities for Zilosul®. The company also reported a strong cash position of A$15.37 million at the quarter's end, demonstrating financial stability to sustain its development and corporate objectives.
Key Points
  • Paradigm Biopharmaceuticals Ltd. focuses on advancing its Phase 3 osteoarthritis program, with key efforts in clinical trials and potential global licensing opportunities for Zilosul®.
  • The company completed a significant institutional Placement and Share Purchase Plan, raising approximately A$21.38 million.
  • Continued execution and funding for the PARA_OA_012 Phase 3 clinical trial are prioritized, with a focus on participant treatment and regulatory activities.
  • An independent safety review of the PARA_OA_012 study identified no material safety concerns.
  • Paradigm engaged in significant business development activities, including attending the BIO International Convention in San Diego.
  • The company reported cash and cash equivalents totaling approximately A$15.37 million at the end of June 2026.
  • Paradigm continues to focus on its scientific and translational activities, including the advancement of MRI structural data manuscripts and collaborations with research institutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.